Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry

Fecha de publicación: 01/08/2022 Fecha Ahead of Print: 01/06/2022

Autores de IIS La Fe

Esther Zorio Grima

Autor
Jose Carlos Sanchez Martinez

Autor

Participantes ajenos a IIS La Fe

Gimeno, Juan R.
Olivotto, Iacopo
Isabel Rodriguez, Ana
Ho, Carolyn Y.
Fernandez, Adrian
Quiroga, Alejandro
Angeles Espinosa, Mari
Gomez-Gonzalez, Cristina
Robledo, Maria
Tojal-Sierra, Lucas
Day, Sharlene M.
Owens, Anjali
Barriales-Villa, Roberto
Maria Larranaga, Jose
Rodriguez-Palomares, Jose
Gonzalez-del-Hoyo, Maribel
Piqueras-Flores, Jesus
Reza, Nosheen
Chumakova, Olga
Ashley, Euan A.
Parikh, Victoria
Wheeler, Matthew
Jacoby, Daniel
Pereira, Alexandre C.
Saberi, Sara
Helms, Adam S.
Villacorta, Eduardo
Gallego-Delgado, Maria
Castro, Daniel
Dominguez, Fernando
Ripoll-Vera, Tomas
Garcia-Alvarez, Ana
Arbelo, Elena
Victoria Mogollon, Maria
Eugenia Fuentes-Canamero, Maria
Grande, Elias
Pena, Carlos
Monserrat, Lorenzo
Lakdawala, Neal K.
Dilema Int Cardiomyopathy Heart Fa

Grupos

Cardiopatías familiares, muerte súbita y mecanismos de enfermedad (CAFAMUSME)

Investigador Principal

Aitana Braza Boils

Abstract

Aims To describe the natural history of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. Methods and results Three hundred and five patients [age 56.6 +/- 16.9 years old, 191 (62.6%) male patients] with HCM and SARS-Cov-2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS-CoV-2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty-nine (22.9%) HCM patients were hospitalized for non-ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS-CoV-2-related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12-4.51], P = 0.02291, baseline New York Heart Association class [OR per one-unit increase 4.01 (95%CI: 1.75-9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16-26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20-49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community-based SARS-CoV-2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98-2.91, P = 0.0600). Conclusions Over one-fourth of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.

Datos de la publicación

ISSN/ISSNe:: 2055-5822, 2055-5822
Tipo:: Article
Páginas:: 2189-2198
DOI:: 10.1002/ehf2.13964
Factor de Impacto:: 0,797 SCImago ℠
Cuartil:: Q2 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Keywords

Hypertrophic cardiomyopathy; COVID-19; SARS-CoV-2 infection; Heart failure; Registry; Prognosis

Campos de estudio

Proyectos asociados

RED INVESTIGACION (RECAVA)

RD06/0014/0004 . INSTITUTO DE SALUD CARLOS III; FUNDACION PARA LA INV BIOMEDICA- HOSPITAL GREGORIO MARAÑON; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2006